Amgen gets early win in Regeneron lawsuit over Eylea biosimilar
Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...
FiercePharma6d
Regeneron's stock drops as it loses bid to block Amgen's Eylea biosimilar
Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for ...
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar ...
Regeneron falls after judge denies injunction blocking Amgen Eylea biosimilar
Regeneron Pharmaceuticals (REGN) drops 3.5% after judge denies motion to block generic version of Eylea, a blockbuster eye ...
STAT6d
Regeneron’s Eylea biosimilar fight heats up
Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its ...
Regeneron downgraded at Leerink after Amgen’s court win; Truist defends
Regeneron (REGN) stock was downgraded by Leerink after a court ruling that favored Amgen's (AMGN) plans to introduce a biosimilar for REGN's Eylea. Read more here.
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Regeneron sued Amgen in January, alleging that it was developing a biosimilar that violated key patent protections for Eylea.
Regeneron Pharmaceuticals Suffers Worst Month in Two Years After Legal Setback
Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...
Regeneron’s Patent Resilience and Market Positioning Justify a Buy Rating
Jefferies analyst Akash Tewari maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of ...